Literature DB >> 21712098

Chiral lipidomics of E-series resolvins: aspirin and the biosynthesis of novel mediators.

Sungwhan F Oh1, Thad W Vickery, Charles N Serhan.   

Abstract

Control of the inflammatory response is of wide interest given its important role in many diseases. In recent years we identified novel mechanisms and lipid mediators that play an active role in stimulating the resolution of self-limited acute inflammation. These novel pro-resolving mediators include the essential fatty acid-derived lipoxins, resolvins, protectins and maresins. Members of each possess a unique pro-resolving mechanism of action; each limits neutrophilic infiltration, regulates local mediators (chemokines, cytokines) as well as stimulates macrophage-enhanced clearance of apoptotic PMN, cellular debris and microbes. Given this unique mechanism of action, resolvins have already been shown to play pivotal roles in regulating key events in a wide range of experimental inflammatory diseases. These pro-resolving mediators also provide a molecular link between omega-3 essential fatty acids (e.g. EPA, DHA) and the resolution process of inflammation and tissue homeostasis. Here, we review recent evidence obtained using chiral LC-MS-MS-based lipidomics to identify a novel 18S-series of resolvins derived from EPA. Resolvin E1 possesses potent actions in vivo and in vitro demonstrated now in many laboratories, and herein we review comparisons in E-series resolvin biosynthesis and action of 18S-resolvin E1 and 18S-resolvin E2. The biosynthesis and formation of both 18S and 18R-series are enhanced with aspirin treatment and involve the utilization of dietary EPA as well as recombinant human 5-lipoxygenase and LTA(4) hydrolase in their stereospecific biosynthesis. Herein we also demonstrate the utility of LC-MS-MS-based lipidomics in identifying resolvins, protectins and related products in marine organisms such as Engraulis (Peruvian anchovy). These new findings emphasize the utility of chiral LC-MS-MS lipidomics and the potential for identifying new resolution circuits with chiral LC-MS-MS-based lipidomics and metabolomics.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21712098      PMCID: PMC3205339          DOI: 10.1016/j.bbalip.2011.06.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  43 in total

1.  A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties.

Authors:  Roberta A Navarro-Xavier; Justine Newson; Vera Lucia Flor Silveira; Stuart N Farrow; Derek W Gilroy; Jonas Bystrom
Journal:  J Immunol       Date:  2009-12-23       Impact factor: 5.422

2.  Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions.

Authors:  Zhen-Zhong Xu; Ling Zhang; Tong Liu; Jong Yeon Park; Temugin Berta; Rong Yang; Charles N Serhan; Ru-Rong Ji
Journal:  Nat Med       Date:  2010-04-11       Impact factor: 53.440

Review 3.  Anti-inflammatory Agents: Present and Future.

Authors:  Charles A Dinarello
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

4.  Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1.

Authors:  Min Wan; Catherine Godson; Patrick J Guiry; Birgitta Agerberth; Jesper Z Haeggström
Journal:  FASEB J       Date:  2011-02-09       Impact factor: 5.191

Review 5.  The relationship between the fatty acid composition of immune cells and their function.

Authors:  Philip C Calder
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-10-23       Impact factor: 4.006

6.  Resolvin E1 receptor activation signals phosphorylation and phagocytosis.

Authors:  Taisuke Ohira; Makoto Arita; Kazuhiro Omori; Antonio Recchiuti; Thomas E Van Dyke; Charles N Serhan
Journal:  J Biol Chem       Date:  2009-11-11       Impact factor: 5.157

7.  Neuroprotectin D1 attenuates laser-induced choroidal neovascularization in mouse.

Authors:  Kristopher G Sheets; Yongdong Zhou; Monica K Ertel; Eric J Knott; Cornelius E Regan; Jasmine R Elison; William C Gordon; Per Gjorstrup; Nicolas G Bazan
Journal:  Mol Vis       Date:  2010-03-02       Impact factor: 2.367

Review 8.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.

Authors:  Charles N Serhan; Nan Chiang; Thomas E Van Dyke
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

9.  Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways.

Authors:  Thea Morris; Melanie Stables; Paul Colville-Nash; Justine Newson; Geoffrey Bellingan; Patricia M de Souza; Derek W Gilroy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

10.  Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.

Authors:  Charles N Serhan; Rong Yang; Kimberly Martinod; Kie Kasuga; Padmini S Pillai; Timothy F Porter; Sungwhan F Oh; Matthew Spite
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

View more
  19 in total

1.  Chiral lipidomics of monoepoxy and monohydroxy metabolites derived from long-chain polyunsaturated fatty acids.

Authors:  Maximilian Blum; Inci Dogan; Mirjam Karber; Michael Rothe; Wolf-Hagen Schunck
Journal:  J Lipid Res       Date:  2018-11-08       Impact factor: 5.922

2.  RvE1 uses the LTB4 receptor BLT1 to increase [Ca2+]i and stimulate mucin secretion in cultured rat and human conjunctival goblet cells.

Authors:  Menglu Yang; Marit Lippestad; Robin R Hodges; Haakon K Fjærvoll; Ketil A Fjærvoll; Jeffery A Bair; Tor P Utheim; Charles N Serhan; Darlene A Dartt
Journal:  Ocul Surf       Date:  2020-04-30       Impact factor: 5.033

Review 3.  Integrative biological analysis for neuropsychopharmacology.

Authors:  Mark R Emmett; Roger A Kroes; Joseph R Moskal; Charles A Conrad; Waldemar Priebe; Fernanda Laezza; Anke Meyer-Baese; Carol L Nilsson
Journal:  Neuropsychopharmacology       Date:  2013-06-26       Impact factor: 7.853

4.  Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation.

Authors:  Anne Barden; Emilie Mas; Kevin D Croft; Michael Phillips; Trevor A Mori
Journal:  J Lipid Res       Date:  2014-09-03       Impact factor: 5.922

5.  Resolvin E2 formation and impact in inflammation resolution.

Authors:  Sungwhan F Oh; Maria Dona; Gabrielle Fredman; Sriram Krishnamoorthy; Daniel Irimia; Charles N Serhan
Journal:  J Immunol       Date:  2012-03-26       Impact factor: 5.422

6.  Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells.

Authors:  Sesquile Ramon; Fei Gao; Charles N Serhan; Richard P Phipps
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

7.  Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways.

Authors:  Jesmond Dalli; Sesquile Ramon; Paul C Norris; Romain A Colas; Charles N Serhan
Journal:  FASEB J       Date:  2015-02-20       Impact factor: 5.191

Review 8.  Targeted lipidomic strategies for oxygenated metabolites of polyunsaturated fatty acids.

Authors:  Giuseppe Astarita; Alexandra C Kendall; Edward A Dennis; Anna Nicolaou
Journal:  Biochim Biophys Acta       Date:  2014-12-05

9.  Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance.

Authors:  Jeremy W Winkler; Sarah K Orr; Jesmond Dalli; Chien-Yee C Cheng; Julia M Sanger; Nan Chiang; Nicos A Petasis; Charles N Serhan
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379

10.  Metabolic Predictors of Incident Coronary Heart Disease in Women.

Authors:  Nina P Paynter; Raji Balasubramanian; Franco Giulianini; Dong D Wang; Lesley F Tinker; Shuba Gopal; Amy A Deik; Kevin Bullock; Kerry A Pierce; Justin Scott; Miguel A Martínez-González; Ramon Estruch; JoAnn E Manson; Nancy R Cook; Christine M Albert; Clary B Clish; Kathryn M Rexrode
Journal:  Circulation       Date:  2018-02-20       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.